PIANO: A national pregnancy registry of women with IBD
This national prospective registry study is conducted to determine whether the rates of birth defects, miscarriages, premature births and other outcomes in women with inflammatory bowel disease (IBD) taking azathioprine/6MP or biologic therapy (Remicade, Humira, Cimzia, Tysabri, Stelara, Simponi, Entyvio, or Xeljanz) are different from those among IBD-affected women not taking these medications.
For more information, please visit the PIANO website.
PIANO Registry (pdf)
The Kattah Lab aims to understand the causes of Inflammatory Bowel Disease. We are particularly interested in how intestinal epithelial cells contribute to disease. The ultimate goal is to develop patient-tailored treatment strategies that maximize efficacy and minimize toxicity for individual patients.
For more information, please visit the Kattah Lab website.
Outpatient IV steroids for Severe Ulcerative Colitis
We are currently recruiting all patients with acute severe ulcerative colitis requiring IV steroids to enroll in a prospective study examining safety and satisfaction of IV steroids in an outpatient setting. If you are a patient who requires IV steroids for a severe UC flare but are able to maintain adequate oral intake and has manageable pain, you may be eligible for this study. Research participation is through completion of questionnaires.
Outpatient IV steroids for Severe Ulcerative Colitis (pdf)
Tigenix: Stem Cells for fistulas in Crohns Disease
The Tigenix (also known as ADMIRE-CDII) study is Phase 3 clinical trial studying the efficacy of a Cx601 stem cell treatment known as Darvadstrocel in treating complex perianal fistulas in patients with Crohn's Disease. The Crohn’s Disease needs to be under control (remission) or only mildly active and patients will need to have already tried at least one type of medication for perianal fistulas which has not been effective enough or has stopped working. Study consists of a 5-7 week screening period followed by 52-week follow up.
Tigenix: Stem Cells for fistulas in Crohns Disease (pdf)
Abbvie: Risankizumab for Ulcerative Colitis
This study is a Phase 3 clinical trial studying a new IL-23 inhibitor Risankizumab on patients with moderate to severe Ulcerative Colitis who have failed one or more biologic therapies. Induction trial can last 12-24 weeks with potential for long term maintenance for responders.
Abbvie: Risankizumab for Ulcerative Colitis (pdf)
For more information, please email [email protected].